Immune-Onc Therapeutics

Ver el organigrama con sus 11 ejecutivos principales

Biografías más buscadas en Immune-Onc Therapeutics

• Charlene Liao, Director, President and Chief Executive Officer
• Austin Gurney, Director
• Jack Donahue, Director

Crear su alerta
para seguir los movimientos de los ejecutivos en Immune-Onc Therapeutics.

Immune-Onc Therapeutics tiene 2.276 competidores entre los que se incluyen Eurofins (Luxemburgo), Lonza (Suiza) y Adaptive Phage Therapeutics (Estados Unidos).

Popular M&A news in Biotecnología

• Histogen has filed for bankruptcy protection  (publicado el 19 de abril de 2024).
• Bruker has announced the acquisition of NanoString Technologies  (publicado el 18 de abril de 2024).
• Vertex Pharmaceuticals has announced the acquisition of Alpine Immune Sciences  (publicado el 16 de abril de 2024).

Otros contactos sugeridos en el sector Biotecnología

• Vik Bajaj - Director en Interline Therapeutics
• Ali Behbahani - Non-Executive Director en Adaptimmune Therapeutics
• Khalil Barrage - Interim Chairman of the Board en Sensorion

Saber más sobre el sector Biotecnología >

Últimos comunicados de prensa de Immune-Onc Therapeutics

• Here are some recent breakthroughs by women-led life sciences companies in the Bay Area - San Francisco Business Times
• Here are six major breakthroughs achieved by Bay Area women-led biotechs - San Francisco Business Times
• Immune-Onc Therapeutics to Present Trial in Progress Poster for Phase 1 Study of IO-202 in Patients with Advanced Solid Tumors at the Society for Immunotherapy of Cancer Annual Meeting — Immune-Onc Therapeutics
• Immune-Onc Therapeutics to Present Trial in Progress Poster for Phase 1 Study of IO-202 in Patients with Advanced Solid Tumors at the Society for Immunotherapy of Cancer Annual Meeting — Immune-Onc Therapeutics
• Immune-Onc Therapeutics Makes Two Presentations of IO-108, a Novel Clinical-Stage Myeloid Checkpoint Inhibitor Targeting LILRB2 (ILT4), at the AACR 2022 Annual Meeting — Immune-Onc Therapeutics
• News — Immune-Onc Therapeutics
• LLS TAP announces five new investments supporting next generation immunotherapies | Leukemia and Lymphoma Society
• Immune-Onc Therapeutics Makes Two Presentations of IO-108, a Novel Clinical-Stage Myeloid Checkpoint Inhibitor Targeting LILRB2 (ILT4), at the AACR 2022 Annual Meeting — Immune-Onc Therapeutics
• Press Release — Immune-Onc Therapeutics
• LLS TAP Announces Five New Investments Supporting Next Generation Immunotherapies | Leukemia and Lymphoma Society
• View more press releases Close

Redes sociales sobre Immune-Onc Therapeutics

• Immune-Onc Therapeutics en Wikipedia, Google News y Yahoo Finance
• Immune-Onc Therapeutics en LinkedIn, Twitter y YouTube

Contactar a través de e-mail con sus ejecutivos Charlene Liao

Llame a Immune-Onc Therapeutics al +1 650...

Ver el organigrama

Register to receive your alert

Señalar un error